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LONGITUDINAL ASSESSMENT OF INFLAMMATORY CYTOKINES AND
SYMPTOM SEVERITY DURING FIRST 100 DAYS AFTER ALLOGENEIC
BMT FOR AML/MDS PATIENTS
Wang, X.S., Cleeland, C.S., Williams, L.A., Reuben, J., Lee, B.-N.,
Mobley, G., Giralt, S. University of Texas M.D. Anderson Cancer
Center, Houston, TX.
BMT patients develop multiple symptoms at nadir after trans-
plantation that include pain, fatigue, poor appetite, and dis-
turbed sleep. Animal models of sickness behavior suggest such
symptoms may be related to increases in inﬂammatory cyto-
kines. The objective of this study was to prospectively assess the
relationship between symptom severity and changes in inﬂam-
matory cytokines. Methods: Weekly symptom assessment with
the M.D. Anderson Symptom Inventory was done for 30 AML/
MDS patients during the ﬁrst 100 days after allogeneic BMT. A
panel of inﬂammatory cytokines (IL-1ra, IL-6, IL-8, IL-10,
IL-12, and TNF-
) was assayed at several time points: pre-
BMT, conditioning, day of BMT, BMT day 1, nadir, and
BMT days 8, 14, 21, 28, 60, and 90-100. Results:
Multiple symptoms peaked at nadir, with some symptoms (fa-
tigue and pain) remaining at high levels after nadir. Physical
symptoms had much larger ﬂuctuations than affective symptoms
during the study. IL-6 and IL-8 showed signiﬁcant increases
during nadir, signiﬁcantly correlating with fatigue, lack of ap-
petite, drowsiness, dry month, and feeling physically sick (all
P  .01). Conclusion: There is an observed relationship be-
tween increased symptom severity levels and increased inﬂam-
matory cytokine (mainly IL-6 and IL-8) levels during the acute
phase of allogeneic BMT in AML/MDS patients. The question
of a causal link between cytokine levels and symptom severity
requires further study.
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DURATION OF ULCERATIVE MUCOSITIS (OM) AND OUTCOMES OF
ALLOGENEIC (AL) HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Sonis, S.1, Vera-Llonch, M.2, Ford, C.1, Lu, J.3, Khazanov, I.1,
Oster, G.2 1Brigham and Women’s Hospital, Boston, MA; 2Pol-
icy Analysis Inc. (PAI), Brookline, MA; 3Amgen Inc., Thousand
Oaks, CA.
Background: OM is a common toxicity of conditioning reg-
imens for HSCT that has been associated with adverse clinical
and economic outcomes. Methods: A retrospective study of
approximately 400 consecutive HSCT recipients with hemato-
logic malignancies was undertaken at a single academic center.
Data were collected via chart review on days with ulcerative
mucositis and selected outcomes including days with fever, days
of parenteral narcotic therapy, incidence of grade III or IV
(Common Toxicity Criteria) infection, mortality at discharge,
total inpatient days (LOS), and total inpatient charges. Data are
reported here for the 281 AL HSCT recipients. Results: Mean
age of study subjects was 41 yrs. Most common diagnoses were
acute (33%) and chronic (19%) myeloid leukemia. Most patients
(96%) received total body irradiation. Fifty-one percent of
grafts were from unrelated donors. The relationship between
duration of ulcerative mucositis and the outcomes of interest is
reported below. Conclusions: Duration of ulcerative mucositis
is associated with worse clinical and economic outcomes in
patients with hematologic malignancies undergoing AL HSCT
(Table 1).
Table 1. Outcomes of AL HSCT in Patients with Hematologic
Malignancies, by Duration of Ulcerative Mucositis
Outcome
Days with Ulcerative Mucositis (Quartile)
P
Value*
I II III IV
n  83 n  70 n  71 n  57
Fever days
(mean, SD)
4.2 (4.6) 4.6 (3.8) 5.7 (4.4) 7.8 (5.1) <.0001
TPN days
(mean, SD)
7.9 (7.8) 8.0 (7.1) 11.9 (7.3) 13.9 (7.3) <.0001
Narcotic therapy
days (mean, SD)
8.2 (6.1) 10.4 (6.1) 13.9 (6.1) 16.9 (4.4) <.0001
Infection (%) 34.0 (41.0) 27.0 (38.6) 30.0 (42.3) 41.0 (71.9) .0012
Mortality (%) 5.0 (6.0) 4.0 (5.7) 11.0 (15.5) 11.0 (19.3) .0040
LOS (mean, SD) 30.7 (12.8) 30.3 (9.2) 35.8 (15.2) 42.1 (14.3) <.0001
Inpatient charges
(mean, SD)
(10 000)
26.0 (20.3) 24.3 (13.3) 32.5 (21.0) 41.4 (23.5) <.0001
*Test for linear trend: Cochran-Armitage for dichotomous mea-
sures, GLM for continuous measures.
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ADOPTIVE TRANSFER OF CHIMERIC CELLS EXTENDS VASCULARIZED
SKIN GRAFT SURVIVAL
Siemionow, M., Jankowska, A., Klimczak, A., Molski, M., Yazici, I.
The Cleveland Clinic Foundation, Cleveland, OH.
Background: Donor bone marrow transplantation (BMT) is con-
sidered to promote chimerism and organ tolerance. The aim of this
study was to introduce immunotherapy with adoptive transfer of
donor-speciﬁc chimeric cells to support graft acceptance and function
in composite tissue allograft transplants. Methods: Ten transplanta-
tions of hematopoietic stem cells (HSC) across MHC barrier were
performed using LBN (RT1n) and ACI (RT1a) donor rats (n 
5/each) to Lewis (RT1l) recipients. Experimental groups were studied
under 7 days of 
-TCRmAb/CsA protocol. Primary chimeras were
created by intraosseous transplantation of 70  106 HSC. Secondary
chimeras were created via adoptive transfer of MACS-sorted primary
chimeric cells to naive Lewis rat. The induction of chimerism and
migratory potential of chimeric cells (for MHC-class I antigens) in
peripheral blood and bone marrow compartment of secondary chi-
meras was evaluated by ﬂow cytometry and immunohistochemistry.
To test therapeutic effect of adoptive transfer, groin ﬂaps of donor
origin were transplanted. Migratory potential and homing of donor-
speciﬁc cells into lymphoid and myeloid organs in chimeras was
evaluated using PKH26 red ﬂuorescent staining technique at each
time point: 2, 7, 35, 64, 100 days after transplantation. Results: In
primary chimeras 9.5-12.0% of donor-speciﬁc chimerism was in-
duced. MACS sorting revealed similar number of 9.0-20.0  106 for
the RT1n and the RT1a chimeric cells. At day 7, adoptive transfer
resulted in secondary chimeras of 10.3-21.0% for the RT1n and
4.6-16.4% for the RT1a antigens. PKH26 positive cells were present
in the bone marrow compartment and in the lymph nodes, spleen and
thymus of recipients at day 100 after BMT. Prolonged donor ﬂap
survival was achieved after adoptive transfer of chimeric cells without
chronic immunosuppression up to 150 days in secondary LBN chi-
meras and 74 days in secondary ACI chimeras. These animals are still
under observation. Conclusions: Adoptive transfer of chimeric cells
resulted in creation of secondary chimeras with stable level of donor
speciﬁc chimerism. As a result, prolonged survival of composite tissue
allograft was achieved without chronic immunosuppression. This ap-
proach may serve as a new therapeutic modality for tolerance induc-
tion in composite tissue allograft transplant recipients.
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